You are here: Industry Insights > Amgen

News List

Amgen and Syapse enter precision medicine collaboration in oncology worldpharmanews
May 07, 2019
Amgen and Syapse enter precision medicine collaboration in oncology
Novartis to globally co-commercialise Amgen’s migraine drug europeanpharmaceuticalreview
May 07, 2019
Novartis has expanded their commercialisation agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine…
Amgen and Syapse enter precision medicine collaboration pharmaceutical-technology
May 05, 2019
Amgen has partnered with Syapse to create observational research analytics for the assessment of cancer therapy outcomes.
Amgen and Astellas Pharma US agree to settlement costs for kickback charges europeanpharmaceuticalreview
May 05, 2019
Amgen and Astellas Pharma US have agreed to pay a total of $124.75 million to settle allegations that they paid kickbacks to Medicare copays for their own medications.
Amgen ignites a social fitness movement to support the fight against heart disease and cancer worldpharmanews
May 05, 2019
Amgen ignites a social fitness movement to support the fight against heart disease and cancer.
AstraZeneca dumps Amgen-partnered drug after midphase fail fiercebiotech
April 28, 2019
AstraZeneca has dropped (PDF) Amgen-partnered autoimmune drug prezalumab from its pipeline. The action follows the failure of the anti-B7RP1 antibody in a midphase Sjöogren’s syndrome trial.
Amgen and Astellas to pay $125m to settle kickback charges pharmaceutical-technology
April 28, 2019
Amgen and Astellas Pharma US have agreed to pay a total of $124.75m to settle allegations that they paid kickbacks to Medicare copays for their own medications.
Amgen prices bone drug Evenity on par with rival Tymlos…… fiercepharma
April 18, 2019
Amgen is pricing its newly approved osteoporosis drug Evenity on par with Radius Health’s competitor anabolic ……
Amgen’s Evenity FDA approved for osteoporosis in postmenopausal women pharmatimes
April 11, 2019
Amgen and UCB have announced the US Food and Drug Administration (FDA) approval of Evenity (romosozumab) for osteoporosis in postmenopausal women at high risk for fracture.
FDA approves Amgen, UCB's postmenopausal osteoporosis drug Evenity firstwordpharma
April 10, 2019
The FDA announced Tuesday that it approved Amgen and partner UCB's Evenity (romosozumab-aqqg) to treat ……

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page